211 related articles for article (PubMed ID: 23321252)
21. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
22. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Mol Cancer Ther; 2015 Jun; 14(6):1404-13. PubMed ID: 25808836
[TBL] [Abstract][Full Text] [Related]
23. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
[TBL] [Abstract][Full Text] [Related]
24. A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model.
Guo K; Huang P; Xu N; Xu P; Kaku H; Zheng S; Xu A; Matsuura E; Liu C; Kumon H
Oncotarget; 2015 Aug; 6(25):21137-47. PubMed ID: 26023798
[TBL] [Abstract][Full Text] [Related]
25. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.
Huang J; Lyu H; Wang J; Liu B
Cancer Lett; 2015 Oct; 366(2):160-72. PubMed ID: 26123662
[TBL] [Abstract][Full Text] [Related]
26. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
[TBL] [Abstract][Full Text] [Related]
27. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.
Zhang M; Zhang Z; Goldman CK; Janik J; Waldmann TA
Blood; 2005 Feb; 105(3):1231-6. PubMed ID: 15383455
[TBL] [Abstract][Full Text] [Related]
29. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
Minematsu T; Iwai M; Sugimoto K; Shirai N; Nakahara T; Usui T; Kamimura H
Drug Metab Dispos; 2009 Mar; 37(3):619-28. PubMed ID: 19056913
[TBL] [Abstract][Full Text] [Related]
30. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
[TBL] [Abstract][Full Text] [Related]
31. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
[TBL] [Abstract][Full Text] [Related]
32. Survivin and YM155: how faithful is the liaison?
Rauch A; Hennig D; Schäfer C; Wirth M; Marx C; Heinzel T; Schneider G; Krämer OH
Biochim Biophys Acta; 2014 Apr; 1845(2):202-20. PubMed ID: 24440709
[TBL] [Abstract][Full Text] [Related]
33. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
Yoon DH; Shin JS; Jin DH; Hong SW; Jung KA; Kim SM; Hong YS; Kim KP; Lee JL; Suh C; Lee JS; Kim TW
Anticancer Res; 2012 May; 32(5):1681-8. PubMed ID: 22593446
[TBL] [Abstract][Full Text] [Related]
34. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
[TBL] [Abstract][Full Text] [Related]
35. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
Kita A; Mitsuoka K; Kaneko N; Nakata M; Yamanaka K; Jitsuoka M; Miyoshi S; Noda A; Mori M; Nakahara T; Sasamata M
J Pharmacol Exp Ther; 2012 Oct; 343(1):178-83. PubMed ID: 22787117
[TBL] [Abstract][Full Text] [Related]
36. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Pise-Masison CA; Radonovich M; Dohoney K; Morris JC; O'Mahony D; Lee MJ; Trepel J; Waldmann TA; Janik JE; Brady JN
Blood; 2009 Apr; 113(17):4016-26. PubMed ID: 19131553
[TBL] [Abstract][Full Text] [Related]
38. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
39. Survivin is a therapeutic target in Merkel cell carcinoma.
Arora R; Shuda M; Guastafierro A; Feng H; Toptan T; Tolstov Y; Normolle D; Vollmer LL; Vogt A; Dömling A; Brodsky JL; Chang Y; Moore PS
Sci Transl Med; 2012 May; 4(133):133ra56. PubMed ID: 22572880
[TBL] [Abstract][Full Text] [Related]
40. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
Kaneko N; Kita A; Yamanaka K; Mori M
Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
